Barcia Emilia, Herrero-Vanrell Rocío, Díez Ana, Alvarez-Santiago Consuelo, López Isabel, Calonge Margarita
Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain.
Exp Eye Res. 2009 Aug;89(2):238-45. doi: 10.1016/j.exer.2009.03.012. Epub 2009 Mar 31.
We tested the short- and long-term ability of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone to reduce ocular inflammation in rabbits elicited by intravitreal lipopolysaccharide (LPS) injection. PLGA microspheres loaded with dexamethasone were prepared by the solvent evaporation technique from an oil/water emulsion and sterilized by gamma irradiation (25 kGy). The microsphere fraction selected was 2:10 (dexamethasone:PLGA) and contained 141 +/- 0.38 microg dexamethasone/mg PLGA. Microsphere diameters were 20-53 microm, and the mean encapsulation efficiency was 92.97 +/- 0.75%. Seven days prior to the induction of panuveitis, 10 mg of dexamethasone-free or dexamethasone-loaded microspheres were injected into the vitreous. Control animals received no injection. Panuveitis was induced in male New Zealand rabbits (2.5-3.0 kg) by intravitreal injection of Escherichia coli LPS. Clinical evaluation, electroretinography and histopathologic studies were performed in short-term studies of 15 days and in long-term studies of 33 days. Efficacy in reducing inflammation was also studied in vitrectomized eyes. In short-term studies eyes injected with dexamethasone-loaded microspheres had less inflammation than control eyes and eyes injected with blank microspheres. Inflammation reverted in all groups by 15 days after LPS injection. A second LPS dose given on Day 30 provoked a high peak of inflammation in control eyes and in those injected with blank microspheres. In contrast, only slight inflammation occurred in eyes injected with dexamethasone-loaded microspheres. Histopathology and electroretinography supported these results. Dexamethasone-loaded microspheres effectively reduced intraocular inflammation caused by LPS in both short- and long-term studies.
我们测试了载有地塞米松的聚乳酸-乙醇酸共聚物(PLGA)微球减轻兔玻璃体内注射脂多糖(LPS)引发的眼部炎症的短期和长期能力。通过溶剂蒸发技术从油/水乳液制备载有地塞米松的PLGA微球,并通过γ射线辐照(25 kGy)进行灭菌。所选微球的比例为2:10(地塞米松:PLGA),每毫克PLGA含141±0.38微克地塞米松。微球直径为20-53微米,平均包封率为92.97±0.75%。在诱发全葡萄膜炎前7天,将10毫克不含地塞米松或载有地塞米松的微球注入玻璃体。对照动物未接受注射。通过玻璃体内注射大肠杆菌LPS在雄性新西兰兔(2.5-3.0千克)中诱发全葡萄膜炎。在15天的短期研究和33天的长期研究中进行临床评估、视网膜电图和组织病理学研究。还在玻璃体切除的眼中研究了减轻炎症的疗效。在短期研究中,注射载有地塞米松微球的眼睛比对照眼睛和注射空白微球的眼睛炎症更少。LPS注射后15天,所有组的炎症均消退。在第30天给予的第二次LPS剂量在对照眼睛和注射空白微球的眼睛中引发了炎症的高峰。相比之下,注射载有地塞米松微球的眼睛仅出现轻微炎症。组织病理学和视网膜电图支持这些结果。在短期和长期研究中,载有地塞米松的微球均有效减轻了LPS引起的眼内炎症。